Sigmoid Signs License Agreement with Pendopharm for UC Drug CyCol

Sigmoid Signs License Agreement with Pendopharm for UC Drug CyCol
Sigmoid Pharma Limited recently signed a licensing agreement with Pendopharm, a division of Pharmascience Inc., based in Montreal, Canada, for the exclusive rights to commercialize CyCol, an oral treatment for colon diseases like ulcerative colitis. The agreement between the companies is for the Canadian market, and also includes an equity investment in Sigmoid. According to Sigmoid, CyCol uses the powerful efficacy of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *